Another study found that AML fueled by repressive transcription factors, such as PML‐RARα fusion oncoproteins (resulting from PML‐RARA) and AML1‐ETO (resulting from the fusion oncogene RUNX1‐RUNX1T1) display high sensitivity to inhibition of PARP. This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.